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Abstract
Purpose: This report describes initiation of apheresis capability in Liberia, Africa to
support a clinical trial of convalescent plasma therapy for Ebola Virus Disease.
Methods: A bloodmobile was outfitted in the United States as a four-bed apheresis
unit with capabilities including pathogen reduction, electronic blood establishment
computer system, designated areas for donor counseling and laboratory testing, and
onboard electrical power generation. After air transport to Liberia, the bloodmobile
was positioned at ELWA Hospital, Monrovia, and connected to the hospital’s power
grid. Liberian staff were trained to conduct donor screening, which included ques-
tionnaire and onsite blood typing and transfusion transmitted infection (TTI) testing,
and plasma collection and processing.
Results: The bloodmobile was operational within 3 weeks after arrival of the
advance team. Of 101 donors who passed the pre-screening questionnaire, 32 were
deferred. Twenty-eight of ninty-nine tested survivors were deferred for positive trans-
fusion transmitted infection (TTI) tests; twenty-one were positive for hepatitis B,
hepatitis C, or human immunodeficiency virus. The majority of donors had type O
blood; all but one were Rh positive. Forty-three survivors donated at least once;
eighty-nine apheresis attempts resulted in eighty-one successful collections.
Conclusions: Apheresis capability was emergently established in Liberia to support
an efficacy trial of Ebola Convalescent Plasma. Extensive cooperation among multi-
national team members, engineers, logisticians, and blood safety technical personnel
at the operational site was required to surmount challenges to execution posed by
logistical factors. The high proportion of positive TTI tests supported the use of a
pathogen reduction system to enhance product safety.
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1 | INTRODUCTION
The Ebola Virus Disease (EVD) outbreak that ravaged West
Africa in 2014–2015 caught the world unprepared for an
effective clinical and research response. Although EVD had
been recognized since 1976 and there had been at least 25
naturally occurring outbreaks since then,1 there were no
known effective treatments. In 2014, the health services of
the severely affected countries of Guinea, Liberia and Sierra
Leone were overwhelmed and medical intervention was lim-
ited. Typically, treatment consisted of fluid and electrolyte
replacement, usually administered orally, with no clinical
laboratory testing for guidance.2–5 Oral administration was
frequently preferred due to high caseloads and limited
resources, including personnel and limited time to work in
personal protective equipment.2
Few candidate therapies were available. Repurposed and
novel small-molecule antiviral drugs were urgently tested in
in-vitro systems and progressively in rodent and non-human
primate (NHP) models, but none had a convincingly positive
therapeutic profile in the latter model.6 Monoclonal antibody
cocktails, for which efficacy in NHP models had been estab-
lished up to 2 years previously, were in extremely short sup-
ply and had not undergone early phase testing.7
A report from the 1995 EVD outbreak in Kikwit, Zaire
(Democratic Republic of Congo since 1997),8 suggested that
administration of whole blood from EVD survivors might
improve survival, but the uncontrolled nature of the data and
limited number of treated patients (N5 8), precluded firm
conclusions. If effective, convalescent blood would presum-
ably confer benefit via anti-EVD immunoglobulins. Passive
immunization with Ebola-immune globulin was demon-
strated to improve outcome in NHP in 2012.9 Although no
conclusive evidence of efficacy of Ebola convalescent
plasma (ECP) for treatment of EVD in humans was avail-
able, several patients repatriated to the United States received
ECP in addition to fluid management and intensive support-
ive care at a resource level not available in the severely
affected countries in West Africa.10,11 Additional treatments,
including Zmapp, brincidofovir, siRNA, and favapiravir,
were deployed with uncertain effectiveness as rapidly as fea-
sible in affected countries in the hope of curbing the spread
and decreasing mortality.11 In September 2014, the World
Health Organization (WHO) issued guidelines for collection
and administration of ECP as an experimental therapy.12
The use of ECP faced multiple challenges: development
and ethical implementation of clinical trial designs to assess
efficacy; rapid deployment of ECP collection in countries
with limited blood collection or blood safety capacity; con-
sistent production of safe blood components under suitable
cold chain conditions; and prevention of harm to or exploita-
tion of donors or clinical trial participants. The most signifi-
cant was defining a statistically realistic but humane
“control” group. Despite evident challenges, three clinical tri-
als of ECP were initiated in response to the WHO call, one
each in Liberia, Guinea, and Sierra Leone.13,14 This report
describes establishment of capability for collection of aphere-
sis plasma in Liberia to support implementation of the first
ECP trial in West Africa during the 2014–2015 outbreak and
results of donor screening and collection from the first 100
survivors who consented to donate plasma.
2 | METHODS
The blood banking and plasma collection community; aca-
demic, governmental and non-governmental organizations
and health care institutions; and philanthropic organizations
provided crucial support for the trial. ClinicalRM, a contract
research organization headquartered in Hinckley, OH, spon-
sored the trial and initiated protocol development in August
2014. These collaborative efforts enabled rapid design of one
protocol for ECP collection from survivors and another for a
therapeutic trial in patients with acute EVD. Protocols were
approved by ethics committees of the participating US aca-
demic institutions (University of North Carolina and Duke
University), the University of Liberia Pacific Institute for
Research and Evaluation (PIRE), and the Liberia Medicines
and Health Products Regulatory Authority. The clinical trial
and plasma collection were conducted according to Good
Clinical Practice (GCP) using the International Conference
on Harmonisation of Technical Requirements for Pharma-
ceuticals for Human Use (ICH) guidelines and applicable
laws and regulations. Informed, written consent was obtained
from all participating subjects.
ECP was collected at the Eternal Love Winning Africa
(ELWA) Hospital near Monrovia, Liberia, to support a clini-
cal trial of convalescent plasma efficacy and safety (clinical
trials.gov NCT02333578), designed in accordance with
WHO recommendations.12 Dr. Jerry Brown, the ELWA
Medical Director, was Principal Investigator. This report
describes the implementation of apheresis capability and
results of screening and ECP collection from December
2014 to May 2015.
2.1 | Objectives and Eligibility
The primary study objective was to pre-qualify potential
donors for ECP donation and collect ECP by apheresis for
clinical trials or compassionate use. The secondary objective
was to assess quantitative and qualitative changes in anti-
EBOV antibody in EVD survivors over a period of 1 year.
The eligible population comprised adult EVD survivors
(diagnosis established by RT-PCR) who had onset of disease
2 years and 60 days prior to donation, and had been dis-
charged 28 days previously from an Ebola Treatment Unit
(ETU). Additional eligibility requirements included good
general health, two negative RT-PCR blood tests for EVD at
48 hours apart; weight 50 kg; hemoglobin 12.0 g/dl;
temperature 37.58C; and negative test results for HIV-1
and HIV-2, hepatitis B, hepatitis C, malaria, and syphilis.
2.1.1 | Donor recruitment and screening
Donor recruitment, consent, initial screening, and qualifying
blood specimen collection were conducted at ELWA. Poten-
tial donors were identified by hospital staff from ELWA-2
discharge lists and contacted directly with study information.
Safeguards to prevent coercion were included in the recruit-
ment and consenting process. Prior to conduct of any study
activities, individual counseling using an ICH-compliant,
IRB-approved research consent process and written consent
form were completed to minimize the risk of survivor
coercion for participation. Subjects were screened for suit-
ability using a modified detailed blood donation question-
naire.15 Subjects underwent a standard focused physical
examination. Blood specimens were collected for Ebola virus
(EBOV) assays conducted at the Liberian Institute for Bio-
medical Research (LIBR) by RT-PCR under the direction of
the US Army Medical Research Institute of Infectious Dis-
ease (USAMRIID). Blood specimens were also collected for
testing for transfusion-transmitted infections (TTIs) using
rapid diagnostic tests (RDT) with a portion stored for future
quantitative determination of binding and neutralizing anti-
EBOV antibodies. Hemoglobin was measured from finger
prick specimens using the CompoLab TS Hemoglobin
Screening Device (Fenwal, a Fresenius Kabi company, Lake
Zurich, IL). Urine beta-human chorionic gonadotropin was
tested in women to ensure they were not pregnant. Blood
Group was determined using GrifolsMDVR cards. Subjects
found to be TTI positive on initial screening were deferred,
counseled in person by the PI, treated if appropriate, and
referred for medical follow-up. All subjects were provided
with a care package to include multivitamins, iron and folate,
and with compensation sufficient to cover time and travel
expenses.
2.1.2 | ECP collection and donor care
Screening results from eligible donors were reviewed by the
PI on the first return visit, (median 6 days, range 1–64 days).
Prior to apheresis, potential donors were provided a meal,
typically fish and rice. Donors were re-screened using the
same questionnaire and procedures. In addition to a physical
examination, potential donors were evaluated to exclude sig-
nificant orthostatic drop in blood pressure. During the dona-
tion process, donors were encouraged to drink 500 ml Ca11
enriched water. Following plasma collection (650 ml), ECP
was treated by pathogen reduction and split into six 100 ml
aliquots, which were frozen within six hours of collection
and managed as fresh frozen plasma (FFP).16 FFP was not
characterized for coagulation or protein factors, as these
assays were not available in Liberia. Donors were eligible to
return for repeat donation every 14 days, provided they con-
tinued to meet eligibility criteria and passed the pre-
screening protocol. Compensation for time and travel was
provided whether the donation was successful or not.
2.1.3 | ECP collection equipment
Donation activities were conducted on the ELWA campus in
a four-bed bloodmobile (Matthews Specialty Vehicles,
Greensboro, NC) outfitted with apheresis machines (PCS2,
Haemonetics Corporation, Braintree, MA), amotosalen/UV
light pathogen reduction system (INTERCEPT, Cerus Cor-
poration, Concord, CA), Fresenius sterile connection device
(Compodock, Fresenius Kabi, Bad Homburg, Germany),
blood establishment computer system (BECS, provided by
BBCS, Auburn, Washington), and interview and laboratory
space. Bloodmobiles were outfitted in the United States as
apheresis units and airlifted to Liberia. Power was supplied
by the primary hospital generators, with two back-up genera-
tors located on board the vehicle.
2.1.4 | Data analysis
Data in this report were entered at the collection site and later
retrieved from the BECS and exported to Microsoft Excel.
Descriptive statistics were calculated using Microsoft Excel;
confidence intervals for proportions were calculated at http://
vassarstats.net/prop1.html.
3 | RESULTS
The ECP efficacy trial was initiated in Liberia in December,
2014. ECP collection for purposes of this trial continued
until May 2015, when enough ECP had been collected to
meet potential requirements of the trial if the EVD outbreak
should resume. Collection of ECP for production of immune
globulin and follow up of donors in a longitudinal study con-
tinued beyond the dates included in this report.
3.1 | Survivor Characteristics
From 5 December 2014 to 30 April 2015, a total of 100 sur-
vivors were pre-qualified by history and consented to donate
ECP. At first visit, survivors ranged in age from 19 to 67
years (346 9 years) and weighed 696 11 kg. Fifty-nine
were males. Hemoglobin was tested in all 100 participants;
99 were tested for TTI and blood type. Hemoglobin was
13.86 1.3 g/dl (14.26 1.1 males, 13.26 1.2 females). The
majority of survivors were blood type O (N5 55, Figure 1).
One donor was A negative; all the others were Rh positive.
3.2 | Deferrals
Disposition of the 100 enrolled participants (Figure 2) shows
99 provided specimens for TTI tests. Thirty-three were
deferred prior to first donation. Twenty-eight were deferred
FIGURE 1 Distribution of ABO groups among screened
survivors
for positive results of one or more TTI (Figures 2 and 3).
Twenty-one (21.2%) of those tested were permanently
deferred for positive HBV, HCV, or HIV tests. Two of the
three survivors testing positive for syphilis were also positive
for one of the permanently deferring tests; the other was pos-
itive for malaria. Six of the seven survivors positive for
malaria were not positive for any other TTI.
3.3 | Collections
Sixty-seven participants remained eligible after initial defer-
rals. Two of these, who were deferred for decreased hemo-
globin, subsequently recovered and returned to donate
(Figure 2). A total of 89 ECP collection attempts were made
from 43 of these 69 eligible donors. Although donors were
permitted to donate as often as every 14 days, the actual
interval between donations ranged from 28 to 118 days, with
a mean of 476 20 days. A minimum of 350 ml of plasma,
the volume required for subsequent processing in the patho-
gen reduction system, was collected and processed success-
fully in 81 (91.0%) attempts. Insufficient volume was
collected in six attempts; two collections were not success-
fully processed.
3.3.1 | Adverse effects
No adverse effects, including hypotensive episodes, were
reported during the plasma collections. Analysis of hemoglo-
bin levels of the 11 donors who donated at least three times
showed no significant decline (Figure 4).
4 | DISCUSSION
This report describes successful establishment of an emer-
gency apheresis capability in Liberia during the 2014–2015
Ebola outbreak. The urgency of the Ebola crisis, limited
functioning infrastructure and variable experience of local
health care personnel informed our decisions on site selec-
tion, staffing, and logistics. The ELWA campus included
ELWA Hospital, which was operational with limited capabil-
ity throughout the outbreak, and ELWA-2, its associated
ETU. The campus had independent primary and backup elec-
trical generator power. Staff were well-trained in use of per-
sonal protective equipment (PPE) and had cared for
numerous EVD patients in ELWA-2. Despite these important
advantages of the ELWA site, there were some challenges.
Initially, no suitable space with climate controlled work areas
was available for the plasma collection process. Generator
capability was marginal. Although provision of bloodmo-
biles outfitted with apheresis equipment mitigated many of
these challenges, bloodmobiles alone did not provide a turn-
key solution.
An advance, multi-national group of subject matter
experts collaborated with onsite hospital technical staff to
commission the apheresis unit and provide training to three
FIGURE 2 Disposition of screened survivors and collection
metrics1
FIGURE 3 Percentage of survivors with positive tests for
TTI
FIGURE 4 Hemoglobin levels prior to repeated donations
ELWA Hospital laboratory technicians. Prior experience for
blood bank operations consisted of occasional whole blood
collection, blood typing and TTI screening by RDT kits.
New training and competencies included the use of apheresis
collection equipment, sterile connection, pathogen inactiva-
tion, equipment and vehicle maintenance, process and equip-
ment validation, quality systems, donor management
practices and use of the BECS system. Liberian staff were
also trained in GCP, including principles of informed con-
sent and appropriate methods to counsel, recruit and qualify
donors for this purpose. Three weeks after the arrival of the
multi-national team, initial visits for donor screening
commenced.
Ongoing mentoring and monitoring of newly trained staff
were essential to identify, solve and teach resolution strat-
egies as new challenges arose. Donor screening, qualification
and product management were designed around a 510(k)
cleared BECS to assure quality and traceability of each pro-
cess step. Electronic data management was relatively novel
for local staff, and internet connectivity in Liberia was often
unstable. As a result, data were frequently collected manually
and subsequently uploaded to the US-hosted system during
the period of this report. However, feasibility of intermittent
uploading was demonstrated in this study.
Although power surges and outages challenged the pro-
ject from the start, there were no equipment failures. A
broadly competent on-site logistical and engineering team,
robust supply chain, and back up for uninterrupted power
supply were essential for successful operations.
We chose to use a pathogen reduction system to treat
ECP immediately after collection to reduce potential risk of
transmission of EBOV, known TTIs and undetected infec-
tious agents. Disease has recurred in EVD survivors who
have had repeated negative blood tests for EBOV.17,18 More-
over, prevalence rates of HCV and HBV are higher in West
Africa than in other, better-resourced regions.19 Automated
donor screening tests were not available in the region, neces-
sitating the use of less-sensitive rapid tests for donor qualifi-
cation. The positive TTI test prevalence in Liberian survivors
reported here may be greater than that previously reported
for the general Liberian population. In 2014, the prevalence
of HIV in Liberia was 1.2% for population aged 15–49
years,20 compared with 4.0% reported here. The 2014 rates
of HBV and HCV positivity in blood donations in Liberia of
7.4% and 2.3%, respectively,19 are slightly less than half the
rates, 16.2% and 5.1%, respectively, in individual donors
reported here. Whether survivor donors have an increased
rate of TTI compared with the general population will
require more extensive investigation. These high rates of
positive TTI tests appear to support the use of pathogen inac-
tivation of blood products to reduce transfusion risk where
possible.
The absence of adverse donor events in this series of 89
collection attempts is noteworthy. Direct donor observation
by training staff did not indicate physiologically important
adverse effects. A critical skill emphasized and role-played
in training involved donor interaction and providing a posi-
tive donor experience. Many donors expressed apprehension
and fear of pain caused by venipuncture. Implementation of
lidocaine pre-treatment at the venipuncture site improved
donor satisfaction and reinforced the concept of donor care.
Other measures to provide for the safety and comfort of the
donors, for example, a light meal and pre-loading with
calcium-enriched oral fluid, may in part account for the low
reported adverse donor events.
Although the nutritional and metabolic status of the
donors was an initial concern, no significant changes were
observed in weight or hemoglobin levels with repeat dona-
tions, perhaps attributable in part to the relatively long mean
interval of 47 days between donations. Assay of serum albu-
min or total protein, which was not available during the
period covered by this report, and confirmatory research to
assess potential negative consequences of repeated plasma
donation in this population would be advisable.
Donors were compensated for travel and time spent for
donations. The issue of compensation was controversial.
Voluntary, non-remunerated blood donation is a pillar of
blood safety in Africa and in many other regions (to discour-
age high risk blood donors) whereas source plasma donors in
developed countries are routinely compensated. Concern
over exploitation of Ebola survivors by providing compensa-
tion (as a possible incentive to donate) was balanced against
a pressing need to support survivors, who faced issues of
prolonged convalescence, stigmatization, isolation, loss of
livelihoods, difficult travel logistics, and bereavement. Local
ethics committees and survivor groups concurred that com-
pensation for time and travel was appropriate for the purpose
of the clinical trial. There is no suggestion that this should be
translated to the practice of national blood services for whole
blood or routine donations of any sort, outside of a period of
crisis.
5 | CONCLUSIONS
This report describes the setup and operation of apheresis
plasma collection activities in West Africa during the 2014–
2015 Ebola outbreak. Eighty-one units of apheresis plasma
were collected by Liberian staff from 43 Liberian EVD survi-
vors to support clinical trials of ECP safety and efficacy in
EVD. Provision of a fully equipped apheresis unit, intensive
training of local staff by an international team of blood safety
and apheresis experts, and ready participation by the EVD
survivor community led to rapid collection of sufficient ECP
to fulfill projected trial requirements. A high rate of deferral
for TTIs in prospective donors supported the use of an amo-
tosalen/UV illumination pathogen reduction system to reduce
transfusion risk. There were no reported adverse effects from
the apheresis procedures; repeat donors maintained stable
weights and hemoglobin levels. After an extended period of
training and remote support dogged by erratic internet con-
nectivity, implementation of a BECS ultimately provided sat-
isfactory management of donor and product data but article-
based backup was essential.
Planning for collection of apheresis plasma in low-
resource settings should include provisions for overcoming
issues of limited and erratic electrical power supply, main-
taining frozen storage capacity, climate control, maintenance
of equipment, and internet connectivity. Despite these chal-
lenges, the processes described in this report can be success-
fully implemented on relatively short notice in low-resource
settings to provide product for further trials of convalescent
plasma for EVD or other infectious diseases. They may also
serve as a resource to support efforts at strengthening blood
safety systems in West Africa.
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